Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Pharma
Takeda snags FDA nod for once-snubbed Eohilia to go after Sanofi
Takeda's Eohilia, as the first FDA-approved oral therapy for eosinophilic esophagitis, will challenge Sanofi and Regeneron's injectable Dupixent.
Angus Liu
Feb 12, 2024 11:18am
Delayed FDA nod moves Lilly into crowded ulcerative colitis field
Oct 27, 2023 11:10am
Novartis targets new fields—and CAR-T—for immunology growth
May 10, 2023 5:00pm
Novartis, UCB set to battle it out in inflammatory skin disease
Apr 10, 2023 4:40pm
FDA authorizes InflaRx's anti-inflammation drug for severe COVID
Apr 4, 2023 5:12pm
AbbVie's Skyrizi clears psoriasis where Cosentyx, Taltz couldn't
Mar 18, 2023 10:00am